Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944512 · ClinicalTrials.gov registry record · Phase 3
Pravastatin to Prevent Preeclampsia
A Phase 3 study, sponsored by The George Washington University Biostatistics Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT03944512 is a Phase 3 study that was terminated before completion, run by The George Washington University Biostatistics Center. The registered enrollment target is 102 participants.
The verdict
NCT03944512, a Phase 3 study, was terminated before completion, sponsored by The George Washington University Biostatistics Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
This study is a double-blind randomized placebo-controlled trial of 1,550 high-risk women to assess whether daily treatment with pravastatin administered early in pregnancy reduces the rate of a composite outcome of preeclampsia, fetal loss and maternal death. Women with a prior history of preeclampsia with preterm delivery less than 34 weeks will be randomized to pravastatin or placebo daily until delivery. Women will have monthly study visits during pregnancy, a follow-up visit at 6 weeks postpartum and children will have follow-up visits at 2 and 5 years of age.
Interventions
- OTHER Placebo
- DRUG Pravastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2019-07-17 |
| Est. Completion | 2024-06-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944512
The ClinicalTrials.gov registry entry for NCT03944512 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The George Washington University Biostatistics Center, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03944512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03944512 about?
NCT03944512 is a clinical study titled "Pravastatin to Prevent Preeclampsia". This study is a double-blind randomized placebo-controlled trial of 1,550 high-risk women to assess whether daily treatment with pravastatin administered early in pregnancy reduces the rate of a composite outcome of preeclampsia, fetal loss and maternal death. Women with a prior history of preeclamp...
What is the current status of trial NCT03944512?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2019-07-17. Estimated completion is 2024-06-20.
What interventions are being tested in trial NCT03944512?
The interventions under investigation include: Placebo (OTHER), Pravastatin (DRUG).
Who is sponsoring clinical trial NCT03944512?
This trial is sponsored by The George Washington University Biostatistics Center, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.